GlassScriptPhysician profile
Robert Brian Rodriguez
NPI 1619236338
$707.15
in general payments reported to CMS, 2019-2025
14 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $130 · 2024: $284 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $136.53 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $134.05 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $123.31 | 2024 | |
| Exact Sciences Corporation | $59.32 | 2023-2025 | Cologuard Collection Kit |
| Averitas Pharma INC. | $53.21 | 2025 | Qutenza |
| Gilead Sciences, INC. | $46.26 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $28.64 | 2022-2025 | Spravato |
| Merck Sharp & Dohme LLC | $23.89 | 2024 | Gardasil, Gardasil 9 |
| Photonicare INC | $20.02 | 2025 | Otosight Middle Ear Scope |
| Intercept Pharmaceuticals, INC. | $18.65 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.39 | 2023 | Gattex |
| Vbi Vaccine (Delaware) INC. | $17.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.08 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.